• Profile
Close

Open-label, add-on trial of cetirizine for neuromyelitis optica

Neurology® Neuroimmunology & Neuroinflammation Feb 14, 2018

Sand IK, et al. - During this trial, the efficacy and tolerability of cetirizine were gauged by the authors as an add-on to standard therapy for neuromyelitis optica (NMO). Findings revealed that the Epworth Sleepiness Scale (ESS) remained fairly consistent throughout the study. Hence, it was determined that the addition of cetirizine to standard therapy was safe and well tolerated in patients with NMO. It also led to a reduction in the relapses.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay